JERUSALEM, Dec. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd.
(NASDAQ: NTEC) ("Intec" or "the Company") today announces it has
entered into a feasibility agreement with GW Research Limited
("GW"), London, U.K. to explore
using the Accordion Pill (AP) platform for an undisclosed research
program.
"We are very excited to collaborate with GW," said Jeffrey A. Meckler, Vice Chairman and Chief
Executive Officer of Intec Pharma. "Through partnerships such as
this, we continue to evaluate the utility of our Accordion Pill
(AP) platform in the development of innovative therapeutics."
Additional details of the agreement were not disclosed.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism.
For more information, visit www.intecpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward looking statements about our
expectations, beliefs and intentions. Forward-looking statements
can be identified by the use of forward-looking words such as
"believe", "expect", "intend", "plan", "may", "should", "could",
"might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and we undertake no duty to update or revise any
such statements, whether as a result of new information, future
events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties,
many of which are outside of our control. Many factors could cause
our actual activities or results to differ materially from the
activities and results anticipated in forward- looking statements,
including, but not limited to, the following: our limited operating
history and history of operating losses, our ability to continue as
a going concern, our ability to obtain
additional financing, our ability to successfully operate our
business or execute our business plan, the timing and cost of our
clinical trials, the completion and receiving favorable results in
our clinical trials, our ability to obtain and maintain regulatory
approval of our product candidates, our ability to protect and
maintain our intellectual property and licensing arrangements, our
ability to develop, manufacture and commercialize our product
candidates, the risk of product liability claims, the availability
of reimbursement, and the influence of extensive and costly
government regulation. More detailed information about the risks
and uncertainties affecting us is contained under the heading "Risk
Factors" included in our most recent Annual Report on Form 10-K
filed with the SEC on March 13, 2020
and in other filings that we have made and may make with the
Securities and Exchange Commission in the future.
Intec Pharma Investor Contact:
Will O'Connor
Stern Investor Relations
+1 212-362-1200
will@sternir.com
View original
content:http://www.prnewswire.com/news-releases/intec-pharma-announces-cannabinoid-research-collaboration-with-gw-pharma-301187976.html
SOURCE Intec Pharma Ltd.